(Q24197467)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127118%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

meta-analysis

0 references

title

Long-acting beta2-agonists for chronic obstructive pulmonary disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127118%20AND%20SRC:MED&resulttype=core&format=json

chronic obstructive pulmonary disease

27 February 2020

main subject

0 references

author

Kayleigh Kew

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127118%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

Chris Mavergames

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127118%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Julia A E Walters

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127118%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

publication date

15 October 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127118%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

27 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127118%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127118%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

CD010177

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127118%20AND%20SRC:MED&resulttype=core&format=json

Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial

27 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Efficacy and safety of inhaled formoterol 4.5 and 9 μg twice daily in Japanese and European COPD patients: phase III study results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Tolerance to bronchodilating effects of salmeterol in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

The severity of airways obstruction as a determinant of treatment response in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Cardiovascular safety of salmeterol in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Cardiovascular events in patients with COPD: TORCH study results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Health status in the TORCH study of COPD: treatment efficacy and other determinants of change

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Methods for therapeutic trials in COPD: lessons from the TORCH trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

The TORCH (towards a revolution in COPD health) survival study protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

ADRB2 polymorphisms and budesonide/formoterol responses in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Relationship between respiratory symptoms and medical treatment in exacerbations of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Cost-effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: an economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Salmeterol & fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airway disease. A 3-month, placebo-controlled comparison of the efficacy and safety of formoterol and salbutamol, followed by a 12-month trial with formoterol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Addition of salmeterol to existing treatment in patients with COPD: a 12 month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Withdrawal from treatment as an outcome in the ISOLDE study of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Self-management education for patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Indacaterol, a once-daily beta2-agonist, versus twice-daily beta-agonists or placebo for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Acute care costs of patients admitted for management of chronic obstructive pulmonary disease exacerbations: contribution of disease severity, infection and chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

The effect of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Combination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Tiotropium versus placebo for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Pulmonary rehabilitation for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Safety of long-acting beta-agonists in stable COPD: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Dissemination and publication of research findings: an updated review of related biases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Inhaled corticosteroids versus long-acting beta2-agonists for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Smoking cessation for chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Inhaled corticosteroids for stable chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Sex Differences in Mortality and Clinical Expressions of Patients with Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

Combined salmeterol and fluticasone for COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

7 January 2021

Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

7 January 2021

Quality of life changes in COPD patients treated with salmeterol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

7 January 2021

Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

7 January 2021

Efficacy of salmeterol xinafoate in the treatment of COPD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010177.PUB2

7 January 2021

10.1002/14651858.CD010177.PUB2

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127118%20AND%20SRC:MED&resulttype=core&format=json

release_wgndzd3dcbhx5o7zbrpmzg2mem

27 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wgndzd3dcbhx5o7zbrpmzg2mem

24 November 2022

mapped directly with Wikidata item

1 reference

Consolidated OpenCitations Corpus – April 2017

2 references

Consolidated OpenCitations Corpus – April 2017